Radiopharm Theranostics Limited announced the appointment of Dr. Susann Brady-Kalnay PhD to the Company's Scientific Advisory Board (SAB). Dr. Brady-Kalnay is a Professor and distinguished faculty researcher in the Department of Molecular Biology & Microbiology at Case Western Reserve University (CWRU), as well as being a Professor of Neurosciences, Pathology and member of the Case Comprehensive Cancer Center. She is also the founder and CSO of diagnostic and prognostic technology business NeoIndicate LLC.

Trained in the fields of cell adhesion and signalling, Dr. Brady-Kalnay's research has focused on development and cancer-related signalling via Receptor Tyrosine Phosphatases. She has been working to develop novel molecular diagnostic, prognostic and theranostic imaging agents. Most recently Dr. Brady-Kalnay has focused her studies on the existence of a key change in proteolysis of the cell-cell adhesion molecule receptor protein phosphatase PTPµ (PTPmu) in human cancer.

She has also received significant recognition for her work including National Institutes of Health (NIH) grants and the renowned R01 Provocative Questions grant and an Academic Industrial Partnership grant from the National Cancer Institute (NCI). Dr. Brady-Kalnay joins Dr. Sara Hurvitz, Professor Eric Aboagye, Dr. Johannes Notni, Dr. Hong Hoi Ting and Dr. David Ulmert on the SAB, chaired by Radiopharm's Chief Medical Officer Professor David Mozley.